PEPTIDE AGONISTS OF GLP-1 ACTIVITY
First Claim
Patent Images
1. A peptide conjugate comprising a peptide X selected from the group consisting of (a) an exendin having at least 90% homology to exendin-4;
- (b) a variant of said exendin wherein said variant comprises a modification selected from the group consisting of between one and five deletions at positions 34-39 and contains a Lys at position 40 having a lipophilic substituent;
or (c) GLP-1 (7-36) (SEQ ID NO;
114) or GLP-1 (7-37) (SEQ ID NO;
123) having at least one modification selected from the group consisting of;
(i) substitution of D-alanine, glycine or alpha-amino isobutyric acid for alanine at position 8 and (ii) a lipophilic substituent; and
Z, a peptide sequence of 4-20.amino acid units covalently bound to said variant, wherein each amino acid unit in said peptide sequence, Z is selected from the group consisting of Ala, Leu, Ser, Thr, Tyr, Asn, Gin, Asp, Glu, Lys, Arg, His, Met, Orn, and amino acid units of the general formula I —
NH—
C(R1)(R2)—
C(═
O)-(1) wherein R1 and R2 are selected from the group consisting of hydrogen, C1-6-alkyl, phenyl, and phenyl-methyl, wherein C1-6-alkyl is optionally substituted with from one to three substituents selected from halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, and phenyl and phenyl-methyl is optionally substituted with from one to three substituents selected from C1-6-alkyl, C2-6-alkenyl, halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, or R1 and R2 together with the carbon atom to which they are bound form a cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-diaminopropanoic acid; and
a pharmaceutically acceptable salt or the c-terminal amide of said peptide conjugate, with the proviso that x is not exendin-4 or exendin-3.
2 Assignments
0 Petitions
Accused Products
Abstract
Novel peptide agonists of GLP-1 activity useful for lowering blood glucose levels. The novel peptides comprise variants of the GLP-1 or the exendin-4 polypeptide sequence and are pharmacologically active and stable. These peptides are useful in the treatment of diseases that benefit from regulation of excess levels of blood glucose and/or regulation of gastric emptying, such as diabetes and eating disorders.
18 Citations
2 Claims
-
1. A peptide conjugate comprising a peptide X selected from the group consisting of (a) an exendin having at least 90% homology to exendin-4;
- (b) a variant of said exendin wherein said variant comprises a modification selected from the group consisting of between one and five deletions at positions 34-39 and contains a Lys at position 40 having a lipophilic substituent;
or (c) GLP-1 (7-36) (SEQ ID NO;
114) or GLP-1 (7-37) (SEQ ID NO;
123) having at least one modification selected from the group consisting of;
(i) substitution of D-alanine, glycine or alpha-amino isobutyric acid for alanine at position 8 and (ii) a lipophilic substituent; and
Z, a peptide sequence of 4-20.amino acid units covalently bound to said variant, wherein each amino acid unit in said peptide sequence, Z is selected from the group consisting of Ala, Leu, Ser, Thr, Tyr, Asn, Gin, Asp, Glu, Lys, Arg, His, Met, Orn, and amino acid units of the general formula I —
NH—
C(R1)(R2)—
C(═
O)-(1) wherein R1 and R2 are selected from the group consisting of hydrogen, C1-6-alkyl, phenyl, and phenyl-methyl, wherein C1-6-alkyl is optionally substituted with from one to three substituents selected from halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, and phenyl and phenyl-methyl is optionally substituted with from one to three substituents selected from C1-6-alkyl, C2-6-alkenyl, halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, or R1 and R2 together with the carbon atom to which they are bound form a cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-diaminopropanoic acid; and
a pharmaceutically acceptable salt or the c-terminal amide of said peptide conjugate, with the proviso that x is not exendin-4 or exendin-3.
- (b) a variant of said exendin wherein said variant comprises a modification selected from the group consisting of between one and five deletions at positions 34-39 and contains a Lys at position 40 having a lipophilic substituent;
-
2-48. -48. (canceled)
Specification